Repurposing mebendazole against triple-negative breast cancer CNS metastasisAdrian Rodrigues, Melanie Hayden Gephart, Sophia B. Chernikova et al.|Journal of Neuro-Oncology|2024Cited by 5
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspectiveElena W.Y. Hsieh, Debra Zack, Ann Eldred et al.|RMD Open|2025Cited by 3
P105 NEX-T CD19 chimeric antigen receptor (CAR) T-cell therapy CC-97540 (BMS-986353): Preclinical and translational evidence of deep B-cell depletion suitable for study in severe refractory autoimmune diseasesGeorg Schett, Amitkumar Mehta, Tatyana Feldman et al.|Poster presentations|2024Cited by 2
Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential SafetyFabian Mueller, Georg Schett, Julie Rytlewski et al.|Blood|2023Cited by 0
Repurposing mebendazole against triple-negative breast cancer leptomeningeal diseaseAdrian Rodrigues, Melanie Hayden Gephart, Sophia B. Chernikova et al.|Research Square|2024Cited by 0